v2.4.0.8
Segment Reporting - Sales of Company's Products (Detail) (USD $)
In Millions, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Segment Reporting Information [Line Items]      
Sales $ 44,033 $ 47,267 $ 48,047
Revenue for the out-license of a pipeline compound 50    
Other pharmaceutical [Member]
      
Segment Reporting Information [Line Items]      
Sales 4,316 [1] 4,333 [1] 4,266 [1]
Pharmaceutical segment [Member]
      
Segment Reporting Information [Line Items]      
Sales 37,437 40,601 41,289
Other segments [Member]
      
Segment Reporting Information [Line Items]      
Sales 6,325 [2] 6,412 [2] 6,428 [2]
Operating segments [Member]
      
Segment Reporting Information [Line Items]      
Sales 43,762 47,013 47,717
Other [Member]
      
Segment Reporting Information [Line Items]      
Sales 271 [3] 254 [3] 330 [3]
Zetia [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 2,658 2,567 2,428
Vytorin [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,643 1,747 1,882
Januvia [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 4,004 4,086 3,324
Janumet [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,829 1,659 1,363
Nasonex [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,335 1,268 1,286
Singulair [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,196 3,853 5,479
Dulera [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 324 207 96
Asmanex [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 184 185 206
NuvaRing [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 686 623 623
Fosamax [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 560 676 855
Follistim AQ [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 481 468 530
Implanon [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 403 348 294
Cerazette [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 208 271 268
Arcoxia [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 484 453 431
Avelox [Member] | Primary Care and Women's Health [Member]
      
Segment Reporting Information [Line Items]      
Sales 140 201 322
Remicade [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 2,271 2,076 2,667
Simponi [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 500 331 264
Isentress [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,643 1,515 1,359
Cancidas [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 660 619 640
PegIntron [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 496 653 657
Invanz [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 488 445 406
Victrelis [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 428 502 140
Noxafil [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 309 258 230
Temodar [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 708 917 935
Emend [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 507 489 419
Cosopt/Trusopt [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 416 444 477
Bridion [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 288 261 201
Integrilin [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 186 211 230
Cozaar/Hyzaar [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,006 1,284 1,663
Primaxin [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 335 384 515
Zocor [Member] | Hospital and Specialty [Member]
      
Segment Reporting Information [Line Items]      
Sales 301 383 456
Propecia [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 283 424 447
Clarinex [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 235 393 621
Remeron [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 206 232 241
Claritin Rx [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 204 244 314
Proscar [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 183 217 223
Maxalt [Member] | Diversified Brands [Member]
      
Segment Reporting Information [Line Items]      
Sales 149 638 639
Gardasil [Member] | Vaccines [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,831 [4] 1,631 [4] 1,209 [4]
ProQuad/M-M-R II/Varivax [Member] | Vaccines [Member]
      
Segment Reporting Information [Line Items]      
Sales 1,306 [4] 1,273 [4] 1,202 [4]
Zostavax [Member] | Vaccines [Member]
      
Segment Reporting Information [Line Items]      
Sales 758 [4] 651 [4] 332 [4]
Pneumovax 23 [Member] | Vaccines [Member]
      
Segment Reporting Information [Line Items]      
Sales 653 [4] 580 [4] 498 [4]
RotaTeq [Member] | Vaccines [Member]
      
Segment Reporting Information [Line Items]      
Sales $ 636 [4] $ 601 [4] $ 651 [4]
[1] Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
[2] Represents the non-reportable segments of Animal Health, Consumer Care and Alliances. The Alliances segment includes revenue from the Company’s relationship with AZLP.
[3] Other revenues are primarily comprised of miscellaneous corporate revenues, third-party manufacturing sales, sales related to divested products or businesses and other supply sales not included in segment results. On October 1, 2013, the Company divested a substantial portion of its third-party manufacturing sales (see Note 3). In addition, other revenues in 2013 reflect $50 million of revenue for the out-license of a pipeline compound.
[4] These amounts do not reflect sales of vaccines sold in most major European markets through the Company’s joint venture, Sanofi Pasteur MSD, the results of which are reflected in Equity income from affiliates. These amounts do, however, reflect supply sales to Sanofi Pasteur MSD.